(MENAFN- Investor Brand Network)
Adageis
was featured in the latest episode of the
BioMedWire Podcast , as part of
IBN's
sustained effort to provide specialized content distribution via widespread syndication channels. Shane Speirs, CEO of Adageis, joined
the program
to provide an introduction to the company's business model.
“Healthcare is a complicated place, and navigating the system is extremely difficult for patients. On the healthcare delivery side, it's also tough. Classically, there have been different reimbursement methods for healthcare services in the United States, but many agree the future is value-based care,” Speirs explained.“What Adageis does is provide a simple solution to healthcare organizations - ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. We offer a solution that meets everyone's needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with... Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”
To view the full press release, visit
About Adageis
Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector. For more information, visit the company's website at
.
NOTE TO INVESTORS:
The latest news and updates relating to Adageis are available in the company's newsroom at
About BioMedWire
BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer
BioMedWire
Austin, Texas
512.354.7000 Office
[email protected]
BioMedWire is powered by
IBN
MENAFN14012025000224011066ID1109091115
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.